JBIO
Jade Biosciences, Inc. Health Care Pharmaceutical Preparations Russell 3000
$14.06Close
$693.4MMarket cap
$8.95 – $26.8552-week range
Nov 12, 2026Next report
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 24 · weaker than 76% of stocks over 12 months
- Far from its high 48% below its 52-week high
- Distribution down-day volume 1.5× up-day volume over 50 sessions
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
48%
1wk
down 3.6%
price change
1mo
up 0.1%
price change
12-month return
up 43%
market up 11% ·
its own up 37%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.1×
price / book
Earnings yield
down 18.8%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 38%
return on equity
Free cash margin
—
-$94.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.1%
$0.85 a day · 2×ATR $12.35
RS
24 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
0.65
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 2 of 8
- 150-day average above the 200-day: passes
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 1242.7% over the year, from 4m to 49m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 10, 2026
Results reaction
Aug 10, 2026+2% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$8.9M | -$23.0M | -$53.2M | -$81.4M | -$74.6M | -$113.5M |
| Net income | -$9.6M | -$23.0M | -$51.5M | -$75.5M | -$69.6M | -$127.4M |
| Earnings per share | — | -$1.87 | -$2.10 | -$2.87 | -$2.44 | -$4.06 |
| Free cash flow | -$7.9M | -$27.6M | -$39.3M | -$56.9M | -$71.2M | -$94.9M |
| Cash | $4.6M | $54.2M | $22.4M | $23.5M | $69.4M | $88.4M |
| Shareholders' equity | -$13.3M | $172.4M | $126.7M | $109.5M | -$46.8M | $332.5M |
| Shares outstanding | 243.08k | 24.41m | 24.72m | 27.76m | 3.67m | 49.32m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 6, 2026 | Annual ↗ | Dec 31, 2025 | 65d |
| Nov 14, 2025 | Quarterly ↗ | Sep 30, 2025 | 45d |
| Aug 13, 2025 | Quarterly ↗ | Jun 30, 2025 | 44d |
| Apr 25, 2025 | Quarterly ↗ | Mar 31, 2025 | 25d |
| Mar 27, 2025 | Annual ↗ | Dec 31, 2024 | 86d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 13, 2024 | Quarterly ↗ | Mar 31, 2024 | 43d |
| Mar 25, 2024 | Annual ↗ | Dec 31, 2023 | 85d |
| Nov 13, 2023 | Quarterly ↗ | Sep 30, 2023 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 30, 2026 | Other events ↗ |
| Aug 10, 2026 | Results ↗ |
| Jul 1, 2026 | Material agreement ↗ |
| Jun 26, 2026 | Director or officer change · Regulation FD ↗ |
| Jun 11, 2026 | Charter or bylaws · Shareholder vote ↗ |
| Jun 4, 2026 | Other events ↗ |
| Jun 1, 2026 | Regulation FD · Other events ↗ |
| May 7, 2026 | Results ↗ |
| Apr 22, 2026 | Director or officer change ↗ |
| Apr 2, 2026 | Director or officer change ↗ |
| Mar 6, 2026 | Results ↗ |
| Jan 5, 2026 | Results · Regulation FD ↗ |